Suppr超能文献

儿童自身免疫性肝病:肝移植的适应证和结果。

Childhood autoimmune liver disease: indications and outcome of liver transplantation.

机构信息

Department of Paediatrics, University of Malaya Medical Centre, Kuala Lumpur, Malaysia.

出版信息

J Pediatr Gastroenterol Nutr. 2010 Mar;50(3):295-302. doi: 10.1097/MPG.0b013e3181bf0ef7.

Abstract

BACKGROUND

Graft rejection and disease recurrence are well-recognized complications of liver transplantation (LT) for autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC). We describe indications and outcome of LT for childhood AIH and AISC.

PATIENTS AND METHODS

Twenty-year retrospective review of a cohort of children (n = 101) with AIH, AISC, or AIH/sclerosing cholangitis overlap syndrome from a single center.

RESULTS

AIH type 1 (AIH1, n = 67) was more common than AIH type 2 (AIH2, n = 18), AISC (n = 8), or overlap syndrome (n = 8). Overall, 18 patients (18%) required LT, the indications being failure of medical therapy (n = 16) and fulminant liver failure (n = 2). Patients with AIH who required LT had a more prolonged prothrombin time at presentation compared with those who did not undergo transplantation (P = 0.01). Patients with AIH1 who received LT had a lower aspartate transaminase (P = 0.009) and alanine transaminase (P = 0.02) levels at initial diagnosis compared with those with AIH1 who did not undergo transplantation. Post-LT, 11 patients (61%) had 18 episodes of rejection, most were steroid sensitive. Disease recurrence was observed in 7 patients (39%, median duration post-LT 33 months), more common in AIH2 (80% recurrence rate), and those taking cyclosporine (71%, 5/7 patients) compared with those taking tacrolimus (18%, 2/11 patients; P < 0.05) and in 3 of 3 children who did not have maintenance steroids post-LT. The overall 5- and 7-year post-LT survival rate was 94% and 88%, respectively.

CONCLUSIONS

LT is a good therapeutic option for progressive AIH and AISC, although recurrence of the primary autoimmune process limits the outcome.

摘要

背景

肝移植(LT)治疗自身免疫性肝炎(AIH)和自身免疫性硬化性胆管炎(AISC)后,移植物排斥和疾病复发是公认的并发症。我们描述了 LT 治疗儿童 AIH 和 AISC 的适应证和结果。

患者和方法

对来自单一中心的一组儿童(n=101)的 AIH、AISC 或 AIH/硬化性胆管炎重叠综合征进行了 20 年的回顾性分析。

结果

AIH 1 型(AIH1,n=67)比 AIH 2 型(AIH2,n=18)、AISC(n=8)或重叠综合征(n=8)更为常见。总体而言,18 例患者(18%)需要 LT,适应证为药物治疗失败(n=16)和暴发性肝衰竭(n=2)。需要 LT 的 AIH 患者与未接受移植的患者相比,初次就诊时的凝血酶原时间延长(P=0.01)。接受 LT 的 AIH1 患者的天冬氨酸转氨酶(P=0.009)和丙氨酸转氨酶(P=0.02)初始诊断水平低于未接受移植的患者。LT 后,11 例(61%)患者发生 18 次排斥反应,大多数对类固醇敏感。7 例(39%,LT 后中位时间 33 个月)发生疾病复发,AIH2 更为常见(80%复发率),接受环孢素治疗的患者(71%,7/11 例)比接受他克莫司治疗的患者(18%,11/11 例;P<0.05)更常见,3 例未接受 LT 后维持性类固醇治疗的患者中也有 3 例复发。LT 后 5 年和 7 年的总体生存率分别为 94%和 88%。

结论

LT 是进展性 AIH 和 AISC 的良好治疗选择,尽管原发性自身免疫过程的复发限制了其结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验